Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trialJosé Ramón Arribas, José M. Gatell, Pierre‐Marie Girard et al.|The Lancet Infectious Diseases|2015Cited by 143
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort studyDaniel K. Nomah, Bibiana Morell, Daniel Podzamczer et al.|The Lancet HIV|2021Cited by 110
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping reviewJorge Palacio‐Vieira, Eva González‐Roca, Juliana Reyes‐Urueña et al.|BMC Public Health|2021Cited by 37
High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patientsElena Yeregui, Anna Rull, Consuelo Viladés et al.|EBioMedicine|2020Cited by 30
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimensJoaquín Burgos, Jorge Palacio, Sergio Moreno‐Fornés et al.|Journal of Antimicrobial Chemotherapy|2022Cited by 22